{
  "docId": "019de070-6ba7-74d1-848b-b84c997820ae",
  "docSlug": "fd4b4c87c265fc439333e9f58c5ae8a7",
  "documentTitle": "Compass Therapeutics | IPO Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 40,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-6ba7-74d1-848b-b84c997820ae/27",
  "deckHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae",
  "deckJsonHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae.json",
  "deckAnchorHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.95,
        "x": 0.02,
        "y": 0.18
      },
      "kind": "list",
      "text": "CTX-8371: Novel PD-1xPD-L1 bispecific identified utilizing Compass CLC and StitchMabs technologies; Mechanism of action: in addition to blocking PD-1 and PD-L1, it drives PD-1 loss from the surface of effector cells; Potent activity in vitro and in vivo",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d422723-6980-434a-8c46-3d322f9e7e1b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.95,
        "x": 0.02,
        "y": 0.5
      },
      "kind": "list",
      "text": "Strategic rationale for next generation checkpoint blocker?: Activity of checkpoint blockers is broad and often durable, however, most patients still do not benefit from checkpoint blockade; CTX-8371 may have enhanced activity in PD-1/PD-L1 approved indications, while maintaining or even improving safety profile; Based on its differentiated mechanism of action, CTX-8371 may have activity in indications which are not currently addressed by PD-1/PD-L1 blockers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4711f29-41ad-402c-90dc-0562372eff4e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.7,
        "x": 0.02,
        "y": 0.06
      },
      "kind": "title",
      "text": "CTX-8371: Next Generation Checkpoint Blocker",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "643739f0-51f3-4d23-b324-2f8888c754dd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "40cde5c2-826f-4f04-8530-83212a9be091",
      "evidence": "list/bullet: Strategic rationale for next generation checkpoint blocker?: Activity of checkpoint blockers is broad and often durable, however, most patients still do not benefit from checkpoint blockade; CTX-8371 may have",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "8f23aa4f-73de-402c-b124-1353a7937adb",
      "evidence": "The deck presents a clear 'why' throughout, with a focus on the team's expertise and the pipeline's potential",
      "position": 1,
      "objective": "Why Compass Therapeutics, and why now?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}